News
Why Medical Conferences Matter in Modern Healthcare
The physical gathering of healthcare professionals, researchers, and industry leaders remains an indispensable cornerstone of progress. Far from being obsolete, medical conferences serve as the high-pressure crucibles where raw data is transformed into clinical wisdom and where the collective...
Business & Industry
Teva, Royalty Pharma $500M Deal to Advance Autoimmune Drug
Teva Pharmaceutical Industries and Royalty Pharma have signed a funding agreement valued at up to $500 million to advance the development of TEV-408, an investigational therapy for autoimmune disorders, including vitiligo. The Teva, Royalty Pharma $500M deal would be...
Drug Research
Pierre Fabre, Iktos Launch AI-Driven Oncology Drug Discovery
An integrated partnership has been formed between Pierre Fabre Laboratories and Iktos to advance AI-driven oncology drug discovery. The collaboration focuses on identifying and developing new small-molecule drug candidates by combining Iktos’ AI and robotics technologies with Pierre Fabre’s...
Business & Industry
Revvity and Lilly Expand Lilly TuneLab Access via Signals
Revvity, Inc. announced a collaboration with Eli Lilly and Company to broaden access to Lilly TuneLab by bringing the platform to the Revvity Signals ecosystem. The collaboration builds on Revvity’s recently launched Signals Xynthetica offering and aims to accelerate...
News
The Role of Therapy in Managing Chronic Stress and Trauma
Have you ever felt like you’re constantly tired, even after a full night’s sleep? Like your mind is always racing, your shoulders are always tense, and peace feels more like a rumor than a reality? If so, you’re not...
News
Is Social Work the Right Career for You? Key Skills and Values
If you have ever felt pulled toward a career where you help people through real challenges, social work may be on your mind. Many people feel interested in this field, but still pause before committing. That hesitation makes sense....
Drug Research
Amgen Eyeing Preclinical Blood Cancer Program to Its Skills
Amgen is going ahead and adding Dark Blue to its tapestry, embedding the preclinical blood cancer program of U.K. biotech into its organization.
The California pharma has gone ahead and stitched together a deal of almost $840 million for Dark Blue Therapeutics, which is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















